Vycor Medical, Inc. announced that it has received $0.62 million in funding from Fountainhead Capital Partners Limited
January 10, 2017
Share
Vycor Medical, Inc. (OTCPK:VYCO) announced a private placement of 2,945,749 common shares at $0.21 per share for gross proceeds of $618,607 with returning investor, Fountainhead Capital Partners Limited on January 11, 2017. Fountainhead Capital Partners Limited invested $404,186 in the transaction. The company also issued 2,945,749 warrants to purchase common share at $0.27 per share for a period of three years. The company issued the securities pursuant to exemption provided under Regulation D. The transaction involved participation from 54 investors.
Vycor Medical, Inc. provides surgical and therapeutic solutions. The Company designs, develops and markets neurological medical devices and therapies. The Company operates through two segments: Vycor Medical and NovaVision. The Vycor Medical segment designs, develops and markets medical devices for use in neurosurgery. The NovaVision segment provides non-invasive rehabilitation therapies for those who have vision disorders resulting from neurological brain damage such as that caused by a stroke. Vycor Medical's product Vycor Medical's ViewSite Brain Access System (VBAS) is a next generation retraction and access system. Vycor Medical focuses on brain and cervical surgical access systems for sale to hospitals and medical professionals. NovaVision's products include Vision Restoration Therapy (VRT), NeuroEyeCoach and Neuro-Eye Therapy (NeEt). The Company operates in the United States and Europe.
VYCOR MEDICAL, INC. 
